The advent of biosimilar medications has offered the promise of significant cost savings for healthcare systems and patients. Biosimilars are highly similar versions of existing biologic drugs, providing a more affordable alternative once the original biologic patent expires. However, the adoption of biosimilars in the U.S. has been hampered by myriad roadblocks, many of which…
As rheumatology fellows around the country begin to explore various career opportunities, they typically look to academic rheumatology, private practice, industry and research. Vivek K. Murthy, MD, MSc, however, has carved a unique clinical pathway in both rheumatology and hospital medicine, merging his various skills and interests in medical education, diagnostic expertise and clinical problem…
Welcome to the first edition of the President’s Corner! I am grateful to Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS, and the editors of The Rheumatologist for their support and encouragement in allowing me to have this opportunity each month to come together with rheumatologists and rheumatology health professionals. So why the President’s Corner? In…
It’s dark. It’s cold. And it’s 5 p.m. here in Iowa. If that sounds rather bleak to you, I wouldn’t blame you. But to Stella, my 12-year-old canine companion, it’s a wonderland. She’s half-Shetland sheepdog and half-American Eskimo, so the colder and snowier it is, the more she feels at home. And although I do…
WASHINGTON, D.C.—For the first time in U.S. history, older adults are projected to outnumber children by 2034, and their care poses unique challenges to the rheumatologist.1 Normal physiologic changes of aging include but aren’t limited to falling renal function, changes in pharmacokinetics and bone density loss. At the ACR Convergence 2024 Review Course, Namrata Singh,…
Dr. Jonas has long sought bold and innovative approaches to workforce challenges in rheumatology. As new chair of the Workforce Solutions Committee, she aims to increase the role of advanced practice providers in rheumatology practices and reduce wait times for specialty care.
Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…
At the ARP Keynote lecture at ACR Convengence 2024, Sandra Mintz, RN, MS, discussed the importance of empathy & trust-building between doctors & their rheumatology patients.
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…
Reviewing the research presented at ACR Convergence 2024 WASHINGTON, D.C.—Despite significant advances that have taken place over the past several years, systemic lupus erythematosus (SLE) still presents great challenges to rheumatologists, given its unpredictable clinical course and the eventual consequences the disease itself and the complexity of its treatments impose on individual patients, their families…